A first-in-human Phase I trial (NCT02792465) demonstrated that CFI-402257, either as monotherapy or in combination with Fulvestrant, exhibited a manageable safety profile in patients with solid tumors, including HR+/HER2– breast cancer. Here, ERBB2 is linked to breast carcinoma.